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Background  and  purpose:  Hyponatremia  is common  and is associated  with  poor  in-hospital  outcomes  in
patients  hospitalized  with  heart  failure  (HF).  However,  it is  unknown  whether  hyponatremia  is associated
with  long-term  adverse  outcomes.  The  purpose  of this  study  was  to  clarify  the characteristics,  clinical
status  on  admission,  and management  during  hospitalization  according  to the  serum  sodium  concen-
tration  on admission,  and  determine  whether  hyponatremia  was  associated  with  in-hospital  as well  as
long-term outcomes  in 1677  patients  hospitalized  with  worsening  HF on index  hospitalization  registered
in  the database  of  the Japanese  Cardiac  Registry  of  Heart  Failure  in  Cardiology  (JCARE-CARD).
Methods  and subjects:  We  studied  the  characteristics  and in-hospital  treatment  in  1659 patients  hospital-
ized  with  worsening  HF by  using  the JCARE-CARD  database.  Patients  were  divided  into  2 groups  according
to  serum  sodium  concentration  on  admission  <135  mEq/mL  (n =  176;  10.6%)  or ≥135  mEq/mL  (n =  1483;
89.4%).
Results:  The  mean  age  was  70.7  years  and  59.2%  were  male.  Etiology  was  ischemic  in  33.9%  and  mean
left  ventricular  ejection  fraction  was 42.4%.  After  adjustment  for covariates,  hyponatremia  was  inde-
pendently  associated  with  in-hospital  death  [adjusted  odds  ratio  (OR)  2.453,  95%  conﬁdence  interval
(CI)  1.265–4.755,  p =  0.008].  It was  signiﬁcantly  associated  also  with  adverse  long-term  (mean  2.1 ± 0.8
years)  outcomes  including  all-cause  death  (OR  1.952,  95% CI  1.433–2.657),  cardiac  death  (OR  2.053,  95%
CI  1.413–2.983),  and  rehospitalization  due  to  worsening  HF (OR  1.488,  95%  CI 1.134–1.953).
Conclusions:  Hyponatremia  was  independently  associated  with  not  only  in-hospital  but also long-term
adverse  outcomes  in patients  hospitalized  with  worsening  HF.
3  Jap© 201
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Hyponatremia, usually deﬁned as a serum sodium concentra-
ion <135 mEq/L, has been observed in ∼20% and consistently an
ndependent risk for all-cause mortality as well as longer length
f stay in hospitalized patients with worsening heart failure (HF)
1–4]. However, most of these studies have been focused on short-
erm outcome with up to 90 days of follow-up. A recent study using
 large individual patient data meta-analysis demonstrated that
yponatremia is a determinant of all-cause death during the follow-
∗ Corresponding author. Tel.: +81 11 706 6970; fax: +81 11 706 7874.
E-mail addresses: htsutsui@med.hokudai.ac.jp,
vsecret@med.hokudai.ac.jp (H. Tsutsui).
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ttp://dx.doi.org/10.1016/j.jjcc.2013.07.012anese  College  of  Cardiology.  Published  by Elsevier  Ltd.  All  rights  reserved.
up of 3 years [3]. This study analyzed only all-cause death and
could not include cardiac death or hospitalization due to worsening
HF for an inherent limitation of meta-analysis using the incorpo-
rated data from both randomized trials and observational studies
[3]. Therefore, little information has been available regarding the
relationship between serum sodium concentration and adverse
outcomes including cardiac death and hospitalization due to
worsening HF. Moreover, most of these previous studies were
performed mainly in the USA and Europe. Therefore, the impact
of hyponatremia on outcomes has not been assessed in a broad
cohort of HF patients encountered in routine clinical practice in
Japan.The Japanese Cardiac Registry of Heart Failure in Cardiology
(JCARE-CARD) studied the characteristics, management, and the
outcomes including death and rehospitalization in a broad sam-
ple of patients hospitalized with worsening HF in Japan [5–13]. The
vier Ltd. All rights reserved.
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in patients with hyponatremia. Patients with hyponatremia were
more often treated with catecholamines, PDE III inhibitor, and
carperitide. Mechanical ventilation, PCI, and hemodialysis were
also more frequently used in them (Table 3).S. Hamaguchi et al. / Journal
CARE-CARD prospectively enrolled patients admitted with wors-
ning HF in a web-based registry at 164 participating hospitals.
The objectives of this study were to clarify the characteristics
f patients, clinical status on admission, and management during
ospitalization according to the serum sodium concentration on
dmission, and determine whether hyponatremia was  associated
ith in-hospital as well as long-term outcomes in 1677 patients
ospitalized with worsening HF on index hospitalization registered
n the JCARE-CARD database [14,15].
aterials and methods
The details of the JCARE-CARD have been described previously
5,8–10,14,15]. Brieﬂy, it registered the patients hospitalized due
o worsening HF as the primary cause of admission. The study hos-
itals were encouraged to register the patients as consecutively
s possible. For each patient, baseline data included (1) demogra-
hy; (2) causes of HF; (3) precipitating causes; (4) comorbidities;
5) complications; (6) clinical status; (7) electrocardiographic and
chocardiographic ﬁndings; (8) laboratory data; and (9) treatments
ncluding discharge medications. The data were entered using a
eb-based electronic data capture (EDC) system licensed by the
CARE-CARD (www.jcare-card.jp).
Using the database of 1677 patients registered in JCARE-CARD
14,15], the present study analyzed the data of (1) patient demo-
raphics, clinical characteristics, vital signs, and laboratory data on
dmission [age, sex, cause of HF, medical history, prior hospitaliza-
ion due to HF, New York Heart Association (NYHA) functional class,
ymptoms and signs, vital signs, laboratory data including serum
odium concentration, and echocardiographic parameters], (2)
edication use before admission [angiotensin-converting enzyme
ACE) inhibitor, angiotensin II receptor blocker (ARB), blocker,
iuretics, digitalis, Ca channel blocker, nitrate, antiarrhythmics,
spirin, warfarin, and statin], (3) in-hospital management (diuret-
cs, inotropic agents, vasodilator agents, and non-pharmacological
rocedures), (4) clinical status during index hospitalization [admis-
ion from emergency room, stay at coronary care unit (CCU), length
f CCU stay, length of stay, and in-hospital death], and (5) long-term
utcomes (all-cause death, cardiac death, and rehospitalization due
o HF). Eighteen (1.1%) patients were excluded with missing data
f serum sodium concentration on admission, resulting in 1659
atients included in this analysis. Hyponatremia was deﬁned as
 serum sodium concentration on admission <135 mEq/L.
tatistical analysis
Patient characteristics and treatments were compared using
earson chi-square test for categorical variables, Student’s t-test
or normally distributed continuous variables, and Mann–Whitney
 test for continuous variables not normally distributed. Mul-
ivariable logistic regression was performed to determine the
dds of in-hospital mortality. The covariates including medical
istory [hypertension, diabetes mellitus, ventricular tachycar-
ia/ventricular ﬁbrillation (VT/VF)], NYHA functional class on
dmission, medication use before hospitalization (ACE inhibitor,
iuretics, aldosterone antagonist, and warfarin), laboratory data
n admission [estimated glomerular ﬁltration rate (eGFR),
emoglobin, and plasma B-type natriuretic peptide (BNP)] were
sed in developing the multivariable logistic regression model. The
elationship between serum sodium concentration and long-term
utcomes was evaluated among patients with the post-discharge
ox proportional hazard models. Relative risk was calculated after
djustment with covariables including age, ischemic etiology, med-
cal history (hypertension, diabetes mellitus, sustained VT/VF, and
rior stroke), NYHA functional class on admission, medication usediology 63 (2014) 182–188 183
on admission (ACE-inhibitor or ARB, blocker, diuretics, aldos-
terone antagonist, and warfarin), and laboratory data on admission
(eGFR, hemoglobin, and plasma BNP). SPSS version 16.0 J for Win-
dows (Chicago, IL, USA) was used for all statistical analyses.
Results
Patient characteristics
The distribution of serum sodium concentration on admis-
sion in the total cohort of study patients is shown in Fig. 1.
The mean and median serum sodium concentrations on admis-
sion were 139.6 ± 4.5 mEq/L and 140.0 mEq/L, respectively, ranging
from 114.0 to 156.0 mEq/L. Out of 1659 patients, 176 patients
(10.6%) had hyponatremia, deﬁned as serum sodium concentration
on admission <135 mEq/L.
Clinical characteristics for the total cohort of patients and those
classiﬁed into 2 groups according to the presence or absence of
hyponatremia are shown in Table 1. The mean age was  70.7 ± 13.5
years and 59.3% were men. The causes of HF were ischemic heart
disease in 33.9%, valvular heart disease in 28.1%, hypertensive heart
disease in 26.4%, and dilated cardiomyopathy in 16.9%. As expected,
mean serum sodium concentration was 130.4 mEq/L in patients
with hyponatremia and 140.7 mEq/L without it.
The mean age and causes of HF were comparable between 2
groups. Patients with hyponatremia more frequently had diabetes
mellitus, prior stroke, sustained VT/VF, and prior hospitaliza-
tion due to HF, but less hypertension. They had worse NYHA
functional class and lower blood pressure on admission. eGFR
and hemoglobin concentration were signiﬁcantly lower in these
patients and plasma BNP levels were signiﬁcantly higher. Echocar-
diographic parameters including left ventricular ejection fraction
(LVEF) were comparable between groups.
Medication use before hospitalization was compared between
groups of patients (Table 2). The use of ACE inhibitor, ARB, and
blocker was  comparable between groups. The use of loop diuret-
ics, aldosterone antagonist, antiarrhythmics, and warfarin was
signiﬁcantly higher in patients with hyponatremia.
In-hospital management
The use of thiazide and spironolactone was signiﬁcantly higherFig. 1. Distribution of serum sodium concentration on admission in patients hospi-
talized with worsening heart failure.
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Table 1
Patient characteristics according to the presence or absence of hyponatremia.
Characteristics Total Hyponatremia No hyponatremia p-Value
n  = 1659 n = 176 n = 1483
Na, mEq/L 139.7 ± 4.5 130.4 ± 4.4 140.7 ± 2.9 <0.001
Age,  yrs (mean ± SD) 70.7 ± 13.5 69.2 ± 14.9 70.9 ± 13.4 0.200
Male,  % 59.3 62.0 58.9 0.441
Causes of heart failure, %
Ischemic 33.9 37.3 33.5 0.327
Valvular 28.1 24.1 28.5 0.229
Hypertensive 26.4 25.3 26.5 0.737
Dilated cardiomyopathy 16.9 12.7 17.4 0.122
Medical history, %
Hypertension 52.1 43.3 53.2 0.017
Diabetes mellitus 30.0 40.0 28.8 0.003
Dyslipidemia 25.9 22.8 26.2 0.350
Hyperuricemia 49.1 50.3 49.0 0.745
Prior stroke 16.4 21.8 15.8 0.047
COPD  5.9 3.0 6.2 0.098
Smoking 37.5 33.5 38.0 0.270
Prior  myocardial infarction 28.2 31.7 27.8 0.297
Atrial  ﬁbrillation 34.9 33.9 35.0 0.780
Sustained VT/VF 6.8 15.7 5.8 <0.001
Prior  hospitalization, % 49.8 62.4 48.4 0.001
NYHA  functional class, %
1 0.9 0.0 1.0 0.033
2 10.5 6.6 11.0
3  45.8 41.6 46.3
4  42.7 51.8 41.7
Symptoms, %
Dyspnea on effort 85.8 81.2 86.4 0.031
Dyspnea at rest 68.9 70.3 68.8 0.671
Fatigue 58.2 58.5 58.1 0.848
Signs,  %
Jugular venous distension 33.6 29.7 34.1 0.456
III  sound 24.3 21.0 24.7 0.563
Rale  51.5 48.3 51.9 0.424
Edema 53.2 51.1 53.5 0.448
Lung  congestion 79.4 81.1 79.2 0.707
Pleural effusion 56.5 52.6 57.0 0.266
Hemodynamics
Heart  rate, bpm 87.9 ± 24.4 84.7 ± 22.1 88.2 ± 24.6 0.165
SBP,  mmHg 134.3 ± 30.3 123.0 ± 29.5 135.6 ± 30.1 <0.001
DBP,  mmHg  75.4 ± 18.2 68.6 ± 17.8 76.2 ± 18.1 <0.001
Laboratory data
eGFR, mL/min/1.73 m2 52.5 ± 24.6 47.7 ± 28.9 53.1 ± 24.0 <0.001
Hemoglobin, g/dL 12.4 ± 4.5 11.5 ± 2.3 12.5 ± 4.7 <0.001
Plasma BNP, pg/mL 880 ± 932 1078 ± 1035 856 ± 916 0.013
Echocardiographic parameters
LV EDD, mm 55.8 ± 10.6 54.8 ± 10.2 55.9 ± 10.6 0.174
LV  ESD, mm 44.0 ± 12.5 43.3 ± 13.4 44.0 ± 12.4 0.549
LVEF,  % 42.4 ± 17.9 42.0 ± 19.4 42.5 ± 17.7 0.532
COPD, chronic obstructive pulmonary disease; VT/VF, ventricular tachycardia/ﬁbrillation; NYHA, New York Heart Association; SBP, systolic blood pressure; DBP, diastolic
blood  pressure; eGFR, estimated glomerular ﬁltration rate; BNP, B-type natriuretic peptide; LV, left ventricular; EDD, end-diastolic diameter; ESD, end-systolic diameter; EF,
ejection fraction. Data are shown as percent or means ± SD.
Table 2
Medication use before hospitalization according to the presence or absence of hyponatremia.
Total Hyponatremia No hyponatremia p-Value
n  = 1659 n = 176 n = 1483
ACE inhibitor, % 26.5 32.4 25.8 0.062
ARB,  % 28.7 25.6 29.1 0.333
ACE  inhibitor or ARB, % 51.0 51.1 51.0 0.968
blocker, % 22.1 23.9 21.9 0.556
Diuretics, % 61.5 67.6 60.8 0.077
Loop  diuretics, % 54.3 61.4 53.5 0.047
Aldosterone antagonist, % 24.1 36.9 22.6 <0.001
Digitalis, % 26.4 27.8 26.3 0.651
Ca  channel blocker, % 24.4 21.6 24.7 0.367
Nitrates, % 22.3 23.3 22.2 0.743
Antiarrhythmics, % 13.9 20.5 13.1 0.007
Aspirin, % 34.3 35.8 34.1 0.661
Warfarin, % 27.5 37.5 26.3 0.002
Statin, % 16.2 17.0 16.1 0.752
ACE, angiotensin-converting enzyme; ARB, angiotensin II receptor blocker.
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Table  3
In-hospital management according to the presence or absence of hyponatremia.
Total Hyponatremia No hyponatremia p-Value
n  = 1659 n = 176 n = 1483
Diuretics, %
Loop, i.v. 70.7 75.0 70.2 0.190
Loop,  p.o. 88.8 86.9 89.0 0.409
Thiazide 5.4 9.1 4.9 0.020
Spironolactone 51.7 59.1 50.8 0.038
Inotropic agents, %
Digoxin, i.v. 10.7 8.0 11.0 0.215
Digoxin, p.o. 33.8 35.8 33.6 0.561
Dopamine 20.3 34.7 18.6 <0.001
Dobutamine 12.7 26.1 11.1 <0.001
Norepinephrine 3.3 6.2 2.9 0.018
PDE  III inhibitor 4.5 8.0 4.0 0.018
Vasodilator agents, %
Nitroglycerin, i.v. 14.5 10.2 15.0 0.086
Isosorbide dinitrate, i.v. 12.1 13.6 11.9 0.498
Nitroglycerin, p.o. 3.1 2.3 3.2 0.513
Isosorbide dinitrate, p.o. 12.1 14.9 11.8 0.242
Carperitide 33.7 40.3 32.9 0.048
Procedures, %
Mechanical ventilation 9.1 14.3 8.5 0.014
PCI  4.0 8.9 3.5 0.001
CABG 1.0 1.8 0.9 0.272
Pacemaker 4.4 7.2 4.0 0.058
Hemodialysis 3.1 7.8 2.6 <0.001
IABP  1.0 1.8 0.9 0.268
PCPS  0.2 0.6 0.1 0.191
LVAD  0.1 0.6 0.1 0.066
PDE, phosphodiesterase; PCI, percutaneous coronary intervention; CABG, coronary artery bypass grafting; DC, direct current cardioversion; IABP, intra-aortic balloon pumping;
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CCPS,  percutaneous cardiopulmonary support; LVAD, left ventricular assist device.
n-hospital outcomes
Of the total cohort of patients, 37.7% were admitted from
he emergency room; 34.8% of them stayed in the CCU, and
ean length of CCU stay was 6.5 ± 10.2 days (median 4.0 days).
ean length of hospital stay was 33.8 ± 34.8 days and the
edian was 25.0 days. Crude in-hospital mortality was  5.7%
Table 4).
Patients with hyponatremia were more often admitted from
mergency room (51.4% versus 36.1%, p < 0.001) and stayed in the
CU (46.0% versus 33.4%, p = 0.001). Moreover, their length of hospi-
al stay was signiﬁcantly longer (43.3 ± 37.0 days versus 32.8 ± 34.4
ays, p < 0.001).
Crude in-hospital mortality was signiﬁcantly higher in patients
ith hyponatremia (13.3% versus 4.6%, p < 0.001). In logistic regres-
ion model with patients without hyponatremia as the reference,
yponatremia was signiﬁcantly associated with in-hospital death
unadjusted odds ratio (OR) 3.029, 95% conﬁdence interval (CI)
.819–5.043, p < 0.001]. Even after adjustment for covariates,
ncluding medical history, NYHA functional class on admission, and
edication use before hospitalization, hyponatremia was indepen-
ently associated with in-hospital death (adjusted OR 2.453, 95% CI
.265–4.755, p = 0.008).
able 4
n-hospital outcomes according to the presence or absence of hyponatremia.
Total Hyp
n  = 1659 n = 
Visit to emergency room, % 37.7 51.
Stay  at CCU, % 34.8 46.
Length of CCU stay, days 6.5 ± 10.2 8.
Length of hospital stay, days 33.8 ± 34.8 43.
In-hospital mortality, % 5.7 13.
CU, coronary care unit. Data are shown as percent or means ± SD.Long-term outcomes
During the follow-up after hospital discharge (mean
776.6 ± 294.9 days, 2.1 ± 0.8 years), the rates of adverse out-
comes were as follows: all-cause death 22.2%, cardiac death 14.7%,
and rehospitalization due to worsening HF  35.6%. Hyponatremia
was signiﬁcantly associated also with adverse long-term outcomes
including all-cause death (OR 1.952, 95% CI 1.433–2.657, p < 0.001),
cardiac death (OR 2.053, 95% CI 1.413–2.983, p < 0.001), rehospi-
talization due to worsening HF (OR 1.488, 95% CI 1.134–1.953,
p = 0.004), and all-cause death or rehospitalization due to worsen-
ing HF (OR 1.685, 95% CI 1.331–2.132, p < 0.001) (Table 5 and Fig. 2).
Even after adjustment with covariables including age, ischemic
etiology, medical history, NYHA functional class on admission,
medication use on admission, and laboratory data on admission,
hyponatremia was  an independent risk factor for all-cause death
(adjusted OR 1.658, 95% CI 1.112–2.473, p = 0.013), cardiac death
(adjusted OR 1.775, 95% CI 1.075–2.929, p = 0.025), and all-cause
death or rehospitalization due to worsening HF (adjusted OR 1.526,
95% CI 1.114–2.042, p = 0.004) (Table 5).
The results of subgroup analysis for all-cause death stratiﬁed
by age (≥70 versus <70 years), sex, comorbidity (hypertension
versus no hypertension and eGFR <60 mL/min/1.73 m2 versus
onatremia No hyponatremia p-Value
176 n = 1483
4 36.1 <0.001
0 33.4 0.001
3 ± 14.9 6.2 ± 9.2 0.060
3 ± 37.0 32.8 ± 34.4 <0.001
3 4.6 <0.001
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Table 5
Relative risk of long-term adverse outcomes associated with hyponatremia.
OR (95% CI) p-Value
All-cause death
Unadjusted 1.952 (1.433–2.657) <0.001
Adjusted 1.658 (1.112–2.473) 0.013
Cardiac death
Unadjusted 2.053 (1.413–2.983) <0.001
Adjusted 1.775 (1.075–2.929) 0.025
Rehospitalization due to heart failure
Unadjusted 1.488 (1.134–1.953) 0.004
Adjusted 1.341 (0.955–1.884) 0.090
All-cause death or rehospitalization
Unadjusted 1.685 (1.331–2.132) <0.001
Adjusted 1.526 (1.114–2.042) 0.004
Relative risk was calculated after adjustment with covariables including
age, ischemic etiology, medical history (hypertension, diabetes mellitus, sus-
tained ventricular tachycardia/ventricular ﬁbrillation, prior stroke), New York
Heart Association functional class on admission, medication use on admission
(angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker,
blocker, diuretics, aldosterone antagonist, warfarin), laboratory data on admis-
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for worsening clinical outcomes in HF. First, hyponatremia may
F
rion (estimated glomerular ﬁltration rate, hemoglobin, plasma B-type natriuretic
eptide). OR, odds ratio; CI, conﬁdence interval.
60 mL/min/1.73 m2), LVEF <40% versus ≥40%, and diuretic use
ersus no diuretic use are shown in Table 6. There was  no signiﬁcant
nteraction in any subgroups. These results showing that hypona-
remia was associated with all-cause death in each subgroup were
imilar to those found on the primary analysis.
iscussion
The present study demonstrated by using the JCARE-CARD
atabase that, among patients hospitalized with worsening HF,
yponatremia was seen in 10.6% of patients. Patients with hypona-
remia had more comorbidities. Plasma BNP was signiﬁcantly
igher, and eGFR and hemoglobin concentration were lower in
hese patients. Importantly, the risks of adjusted in-hospital mor-
ality as well as long-term adverse outcomes including all-cause
ig. 2. Kaplan–Meier survival curves free from all-cause death (A), cardiac death (B), 
ehospitalization (D) according to the presence or absence of hyponatremia.diology 63 (2014) 182–188
death, cardiac death, and rehospitalization due to HF  were signiﬁ-
cantly higher in patients with hyponatremia.
The present study demonstrated that hyponatremia was
associated with not only adverse in-hospital but also long-term
outcomes in patients hospitalized with worsening HF. The present
results were consistent with previous reports [1–4]. The Outcomes
of a Prospective Trial of Intravenous Milrinone for Exacerbations of
Chronic Heart Failure (OPTIME-CHF) study identiﬁed a substantial
risk of short- and intermediate-term clinical events associated
with decreasing serum sodium concentration in patients hospi-
talized for worsening HF [1]. Lower serum sodium concentrations
on admission remained a predictor of increased number of days
hospitalized for cardiovascular causes and increased mortality
within 60 days of discharge even after adjustment for a variety
of baseline variables [1]. In the OPTIMIZE-HF registry, low serum
sodium was  more common among patients with lower admission
systolic blood pressure and a prior history of HF [2]. After adjusting
for differences with multivariable analysis, the risk of in-hospital
death increased by 19.5%, for each 3 mmol/L decrease in patients
with serum sodium <140 mmol/L [2]. The Italian Registry on Heart
Failure Outcome (IN-HF) also demonstrated that hyponatremia
(serum sodium concentration <136 mEq/L) was one of the indepen-
dent predictors of in-hospital mortality (OR 2.00, 95% CI 1.26–3.19,
p = 0.004) [16]. However, these studies have primarily focused
on in-hospital and early post-discharge mortality. Moreover, the
OPTIME-CHF study, was performed using the patient data derived
from a large clinical trial with restricted inclusion criteria, such as
markedly reduced LVEF of ≤30%, lower serum creatinine levels of
≤3 mg/dL, and systolic blood pressure ≥80 mmHg [1]. The present
study extended the prognostic impact of hyponatremia during the
long-term follow-up over 2 years and more importantly to a non-
selected HF population encountered in routine clinical practice by
analyzing the registry data of hospitalized HF patients in Japan.
There are several mechanisms of hyponatremia responsibledirectly reﬂect the reduction of cardiac output. Reduced car-
diac output decreases renal perfusion and GFR. Previous studies
[17–19] including our own  [6] demonstrated that reduced GFR was
rehospitalization due to worsening heart failure (HF) (C), and all-cause death or
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Table  6
Subgroup analysis for relative risk of all-cause death associated with hyponatremia.
Subgroup n OR for all-cause death 95% CI p-Value
Na <135 mEq/L vs. ≥135 mEq/L Between groups Interaction
Age <70 years old 558 2.257 1.300–3.920 0.004
0.767Age  ≥70 years old 805 2.042 1.405–2.968 <0.001
Male  807 2.046 1.396–2.998 <0.001
0.699Female 556 1.827 1.080–3.092 0.025
Hypertension 708 1.945 1.184–3.197 0.009
0.981No  hypertension 646 1.920 1.293–2.852 0.001
eGFR  <60 mL/min/1.73 m2 867 1.940 1.395–2.696 <0.001
0.442eGFR  ≥60 mL/min/1.73 m2 494 1.362 0.544–3.413 0.510
LVEF  < 40% 592 1.544 0.927–2.573 0.095
0.373LVEF ≥40% 629 2.125 1.333–3.386 0.002
Diuretic use 838 2.021 1.442–2.832 <0.001
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GFR, estimated glomerular ﬁltration rate; LVEF, left ventricular ejection fraction; O
ssociated with worsening outcomes in patients with HF. Second,
ormonal abnormalities are also important factors of hypona-
remia in HF. Renin-angiotensin-aldosterone system (RAAS) and
ympathetic nervous system (SNS) are activated in HF [20,21].
ncreased SNS and RAAS cause renal vasoconstriction and reduce
FR. These hormonal abnormalities also increase the retention
f sodium and water, and induce the release of arginine vaso-
ressin (AVP). AVP increases vascular resistance and also increase
ree water retention [22–24]. It also directly and adversely affects
yocardial contractility and cell growth [25]. Finally, hypona-
remia may  also result from the use of diuretics. Diuretic use has
een consistently reported to be associated with long-term adverse
utcomes in previous studies [26,27] including our own [28]. There-
ore, it is not clear whether hyponatremia is directly associated with
dverse outcomes in HF or only a marker of more advanced status
f HF which requires the use of diuretics.
Given the prognostic role of hyponatremia in HF, the treat-
ent of hyponatremia may  improve outcomes in patients with HF.
olvaptan is a V2 receptor antagonist approved for the treatment
f hyponatremia (serum sodium <125 mEq/L) in patients with cir-
hosis, HF, and syndrome of inappropriate anti-diuretic hormone
ecretion in the USA and also ﬂuid retention in HF patients in Japan.
olvaptan signiﬁcantly increased serum sodium concentration in
he Efﬁcacy of Vasopressin Antagonism in Heart Failure Outcome
tudy With Tolvaptan (EVEREST). However, it had no beneﬁcial
ffects on long-term mortality or HF-related morbidity [29]. Fur-
hermore, in the subanalysis of the EVEREST study for HF patients
ith hyponatremia (11.5% of total cohort), tolvaptan use was  asso-
iated with greater likelihood of normalization of serum sodium,
reater weight reduction at day 1 and discharge, and greater relief
f dyspnea than placebo. However, long-term outcomes were com-
arable between patients with tolvaptan and placebo. Only in 92
atients with pronounced hyponatremia (<130 mEq/mL), tolvaptan
as associated with reduced cardiovascular morbidity and mortal-
ty after discharge (p = 0.04) [30]. Further clinical studies are clearly
eeded to determine the effects of tolvaptan on the outcomes of
yponatremic HF patients. Moreover, tolvaptan is not necessarily a
herapeutic tool for hyponatremia, and is one of diuretics. Thus, it
ay  not be easy to clarify the effects of a therapeutic intervention
gainst hyponatremia by analyzing the effects of tolvaptan.
tudy limitationsSeveral limitations inherent in the design of the registry should
e considered in this study. First, the documentation of serum
odium concentration levels on admission might not accurately0.3550.615–2.938 0.459
ds ratio; CI, conﬁdence interval.
reﬂect those after discharge or their changes over time. Second,
the present study was not a prospective randomized trial and,
despite covariate adjustment, other measured and unmeasured
factors might have inﬂuenced outcomes. Third, we  did not collect
information regarding the dose of loop diuretics and cannot assess
its relation to prognosis. Loop diuretic use can induce hyponatremia
and has been demonstrated to be associated with worse outcomes
in our previous study [28]. Finally, data were dependent on the
accuracy of documentation and abstraction by individual cardiolo-
gists that participated in this study.
Conclusions
Hyponatremia was observed in 10% of patients hospitalized with
worsening HF. It was  independently associated with in-hospital
as well as long-term adverse outcomes in these patients. Further
studies are needed to establish serum sodium concentration as a
potential therapeutic target for HF.
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